Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Aug;104(2):228-230.
doi: 10.1016/j.kint.2023.04.022. Epub 2023 May 22.

APOL1 channel blocker reduces proteinuria in FSGS

Opeyemi A Olabisi  1
Affiliations
Comment

APOL1 channel blocker reduces proteinuria in FSGS

Opeyemi A Olabisi. Kidney Int. 2023 Aug.
No abstract available

Keywords: chronic kidney disease; focal segmental glomerulosclerosis; nephrotic syndrome.

PubMed Disclaimer

Figures

Figure 1 |
Figure 1 |. Kidney disease–associated APOL1 variants (G1 and G2) proteins form cation pores at the plasma membrane (PM) that transport Na+ and K+ down their concentration gradients across the PM, thereby causing podocyte injury.
Inaxaplin specifically blocks the aberrant cation channel function of G1 and G2 and thereby prevents podocyte injury. Egbuna et al. reported that Inaxaplin reduced proteinuria in APOL1-associated FSGS. Inhibition of APOL1 production either by blocking JAK-STAT signaling or by APOL1 antisense oligonucleotide is an alternative therapeutic strategy that is under investigation.
See this image and copyright information in PMC

Comment on

  • Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.
    Egbuna O, Zimmerman B, Manos G, Fortier A, Chirieac MC, Dakin LA, Friedman DJ, Bramham K, Campbell K, Knebelmann B, Barisoni L, Falk RJ, Gipson DS, Lipkowitz MS, Ojo A, Bunnage ME, Pollak MR, Altshuler D, Chertow GM; VX19-147-101 Study Group. Egbuna O, et al. N Engl J Med. 2023 Mar 16;388(11):969-979. doi: 10.1056/NEJMoa2202396. N Engl J Med. 2023. PMID: 36920755 Clinical Trial.

References

    1. Friedman DJ, Pollak MR. APOL1 nephropathy: from genetics to clinical applications. Clin J Am Soc Nephrol. 2021;16:294–303. - PMC - PubMed
    1. US Renal Data System. 2017 USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2017.
    1. Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008;40:1185–1192. - PMC - PubMed
    1. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40:1175–1184. - PMC - PubMed
    1. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329:841–845. - PMC - PubMed

LinkOut - more resources